Rotigotine 2 mg/Day 24HR Transdermal System (7) / rotigotine 4 mg/Day 24HR Transdermal System (7) Pack
RxNorm 1360632

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1360632 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: rotigotine 2 mg/Day 24HR Transdermal System (7) / rotigotine 4 mg/Day 24HR Transdermal System (7) Pack.

The following semantic concepts and normalized strings are associated with this clinical entity:

PSN
Rotigotine 2 mg/Day 24HR Transdermal System (7) / rotigotine 4 mg/Day 24HR Transdermal System (7) Pack
AUI:8246891
View
GPCK
{7 (24 HR rotigotine 0.0833 mg/HR Transdermal System) / 7 (24 HR rotigotine 0.167 mg/HR Transdermal System) } Pack
AUI:12372782
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PSNPrescribable

Prescribable Name (PSN):
Rotigotine 2 mg/Day 24HR Transdermal System (7) / rotigotine 4 mg/Day 24HR Transdermal System (7) Pack
(Atom ID: 8246891)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
rotigotine 2 MG/Day 24HR Transdermal System (7) / rotigotine 4 MG/Day 24HR Transdermal System (7) Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1360632
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
8246891
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
1360632
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
GPCKPrescribable

Generic Pack (GPCK):
{7 (24 HR rotigotine 0.0833 mg/HR Transdermal System) / 7 (24 HR rotigotine 0.167 mg/HR Transdermal System) } Pack
(Atom ID: 12372782)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{7 (24 HR rotigotine 0.0833 MG/HR Transdermal System) / 7 (24 HR rotigotine 0.167 MG/HR Transdermal System) } Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1360632
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12372782
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
GPCK
Generic Pack ({# (Ingredient + Strength + Dose Form) / # (Ingredient + Strength + Dose Form)} Pack)
Source Code
1360632
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN HUMAN DRUG
US
Drug available for use in Humans

Patient Education

Rotigotine Transdermal Patch


Rotigotine transdermal patches are used to treat the signs and symptoms of Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance) including shaking of parts of the body, stiffness, slowed movements, and problems with balance. Rotigotine transdermal patches are also used to treat restless legs syndrome (RLS or Ekbom syndrome; a condition that causes discomfort in the legs and a strong urge to move the legs, especially at night and when sitting or lying down). Rotigotine is in a class of medications called dopamine agonists. It works by acting in place of dopamine, a natural substance produced in the brain that is needed to control movement.
[Learn More]


* Please review the disclaimer below.